Research programme: respiratory disorder therapeutics - PARI Pharma

Drug Profile

Research programme: respiratory disorder therapeutics - PARI Pharma

Alternative Names: Disodium Cromoglycate - PARI; DSCG - PARI Pharma; Levofloxacin VibrENT; Sodium cromoglicate - PARI Pharma

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator PARI Pharma GmbH
  • Class Benzopyrans; Chromones; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Mast cell stabilisers; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Rhinosinusitis

Highest Development Phases

  • No development reported Rhinosinusitis
  • Discontinued Asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rhinosinusitis in Germany (Inhalation)
  • 11 Sep 2013 Research programme: respiratory disorder therapeutics - PARI Pharma is available for licensing as of 11 Sep 2013.
  • 26 Jan 2010 Preclinical trials in Rhinosinusitis in Germany (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top